Pharmabiz1h
ProMIS Neurosciences begins patient dosing in phase 1b PRECISE-AD trial of PMN310 for Alzheimer’s disease
Massachusetts, Cambridge Saturday, March 1, 2025, 18:00 Hrs [IST] ...
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial
PrimeC has been given an ‘Orphan Drug’ status by the FDA (Food and Drug Administration) and EMA (European Medicines Agency).
Clene Inc. (NASDAQ: CLNN) Leverages APST's Nfl Database To Support FDA-Recommended Analyses For ALS Drug
Clene is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8® in ALS p ...
American Association of Individual Investors18h
Which Is a Better Investment, Alnylam Pharmaceuticals, Inc. or argenx SE Stock?
Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...
ALS News Today20h
Fat molecules may limit damage to nerve cells in ALS, study finds
Fat molecules known as PUFAs can help lessen nerve damage in amyotrophic lateral sclerosis (ALS), a study suggests.
Why are flags at half staff today? Find out why NJ flags are lowered
New Jersey Governor Phil Murphy has ordered flags fly half-staff to honor the life of a Garden State legislator who died on Feb. 19. Find out more ...
Who is eligible for both Medicare and Medicaid in California? Beneficiaries with dual eligibility
In California, some individuals qualify for both Medicare and Medi-Cal, a status known as dual eligibility or "Medi-Medi." ...
weedworthy23h
ALS and the Potential of Cannabis-Based Therapies: Insights from Dr. Ethan Russo
On February 20, 2025, CReDo Science presented, “Update on ALS: Amyotrophic Lateral Sclerosis, Cannabis, and Hope for the Future,” an hour-long webinar in which Ethan Russo, MD, neurologist and medical ...